WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524838
CAS#: 194098-25-4
Description: CP-409092 is a GABA(A) partial agonist developed for the treatment of anxiety.
Hodoodo Cat#: H524838
Name: CP-409092
CAS#: 194098-25-4
Chemical Formula: C17H19N3O2
Exact Mass: 297.15
Molecular Weight: 297.350
Elemental Analysis: C, 68.67; H, 6.44; N, 14.13; O, 10.76
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CP-409092; CP409092; CP 409092; UNII-420WLS764W.
IUPAC/Chemical Name: 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-((methylamino)methyl)phenyl)-4-oxo-
InChi Key: XFJIYNUISLDNLP-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H19N3O2/c1-18-9-11-5-7-12(8-6-11)20-17(22)13-10-19-14-3-2-4-15(21)16(13)14/h5-8,10,18-19H,2-4,9H2,1H3,(H,20,22)
SMILES Code: CNCc1ccc(NC(=O)c2c[nH]c3CCCC(=O)c23)cc1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 297.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Kamel A, Colizza K, Gunduz M, Harriman S, Obach RS. In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. Xenobiotica. 2012 Apr;42(4):355-62. doi: 10.3109/00498254.2011.630490. Epub 2011 Nov 22. PubMed PMID: 22106962.
2: Sawant AD, Miller EL, Duignan DB, Brodfuehrer J, Winter SM, Nelson FR, Kamel A, Obach RS, Vaz AD. Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica. 2010 Jul;40(7):476-84. doi: 10.3109/00498254.2010.481057. PubMed PMID: 20429841.
3: Kamel A, Obach RS, Tseng E, Sawant A. Metabolism, pharmacokinetics and excretion of the GABA(A) receptor partial agonist [(14)C]CP-409,092 in rats. Xenobiotica. 2010 Jun;40(6):400-14. doi: 10.3109/00498251003710269. PubMed PMID: 20334492.
4: Sutton SC, Evans LA, Fortner JH, McCarthy JM, Sweeney K. Dog colonoscopy model for predicting human colon absorption. Pharm Res. 2006 Jul;23(7):1554-63. Epub 2006 Jun 21. PubMed PMID: 16783662.
